Dr. Eric Ostertag, CEO Transposagen Biopharmaceuticals
-
Apr 15, 2009 -
Transposagen Biopharmaceuticals, Inc., based in Lexington, KY, has announced today that they have entered into an agreement with Trans Genic, Inc., (Tokyo Stock Exchange Mothers Section, Code: 2342) headquartered in Kumamoto Japan, for the non-exclusive rights to market Transposagen’
s products in Japan. Trans Genic conducts various kinds of businesses related to genetically engineered mice, and introduces many novel technologies, products and services of biotech companies useful for drug discovery to the Japanese market. This agreement is one of these efforts.
Transposagen’
s signature product, the TKOTM Knockout Rat, is a laboratory rat with a single gene disruption that mimics a human disease. At the end of March 2009, Transposagen listed on its public database over 70 different knockout rat lines. Over 90% of the world’s knockout rat lines have been created using Transposagen’
s technology, making Transposagen the worldwide leader in the production of knockout rat lines. The database of available knockout rat lines can be found at
http://www.knockoutrat.org.
“Trans Genic is a leader in Japan in the development and distribution of genetically engineered laboratory animals,” said Eric Ostertag, CEO of Transposagen Biopharmaceuticals, Inc. “This is an exciting opportunity for Transposagen, Trans Genic, and pharmaceutical researchers in the Japanese market.”
Photo:
http://www.prlog.org/10217075/1About Transposagen Biopharmaceuticals:
Transposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models. These models mimic human diseases and are used for drug discovery and development research. The production of animal models is a $1.2 billion/year market and is expected to grow 12% annually through 2012. For more information, visit
http://www.transposagenbio.com.
